Cellular Origins, a TTP Company, has acquired the ACTIA Platform IP, developed by Geoff Hodge, to accelerate the development of their robotic solution for automated cell therapy manufacturing, Constellation™. The platform integrates with existing bioprocessing equipment, allowing for increased capacity and flexibility in manufacturing autologous cell therapies. This acquisition is part of Cellular Origin’s commitment to creating efficient and scalable solutions for cell therapy manufacturing. The combined technologies aim to revolutionize the field by enabling large-scale production of cell therapies, making them more accessible and affordable for patients in need.
Source link
Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing
